VENLO, Netherlands, April 6, 2017 /PRNewswire/ --
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans to release itsreport on results for the first quarter of 2017 on Tuesday, May 2, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Standard Time (EST). A conference call is planned for
The dates for reporting results for the first quarter of 2017 have been moved forward by one day, respectively, compared to the previously announced provisional dates.
Conference Call and Webcast Details
The conference call will begin at 15:00 CET / 9:00 EST on May 3, 2017. Interested parties may listen to the call by dialing: +1-760-294-1674 (U.S.), +44-203-059-5869 (UK), +49-69-566-037-000 (Germany).
The webcast will be accessible at http://www.qiagen.com/de/about-us/investors/corporate-calendar.
A conference call replay will be available through May 10, 2017, by dialing:
+1-724-5589-653 (U.S.), +44-121-260-4861 (UK), +49-69-710-488-70 (Germany) (passcode: 574786#).
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Contact: John Gilardi Vice President, Head of Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Email: email@example.com Dr.Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: firstname.lastname@example.org
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All